Stoke Therapeutics, Inc. (STOK) Tops Q1 EPS by 5c

Stoke Therapeutics, Inc. (NASDAQ: STOK) reported Q1 EPS of ($0.57), $0.05 better than the analyst estimate of ($0.62). Revenue for the quarter came in at $4.2 million versus the consensus estimate of $3.21 million.

For earnings history and earnings-related data on Stoke Therapeutics, Inc. (STOK) click here.

You May Also Be Interested In

• Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
• AutoZone (AZO) Tops Q4 EPS by $1.76, Misses on Revenue
• Societe Generale SA (GLE:FP) (SCGLY) PT Raised to EUR83 at JPMorgan